NCT01044212

Brief Summary

The purpose of this study is to assess the effect of a standardized postoperative bowel regimen of over-the-counter medications in subjects undergoing minimally invasive urogynecologic surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
72

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2009

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2009

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

January 5, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 7, 2010

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2011

Completed
4.7 years until next milestone

Results Posted

Study results publicly available

October 21, 2015

Completed
Last Updated

October 21, 2015

Status Verified

September 1, 2015

Enrollment Period

1.3 years

First QC Date

January 5, 2010

Results QC Date

September 14, 2012

Last Update Submit

September 21, 2015

Conditions

Keywords

Urogynecology

Outcome Measures

Primary Outcomes (1)

  • Time to First Post-op Bowel Movement

    The time to first post-operative bowel movement was measured in hours after surgery.

    Within 1 week of surgery

Secondary Outcomes (2)

  • Pain Level Associated With First Postoperative Bowel Movement

    Within 1 week of surgery

  • Consistency of First Postoperative Bowel Movement

    Within 1 week of surgery

Study Arms (2)

Docusate

ACTIVE COMPARATOR

Docusate is the standard of care regimen

Drug: Docusate

Bowel medications

EXPERIMENTAL

Docusate, Miralax, Metamucil wafers, Bisacodyl suppository

Drug: Bowel medications

Interventions

Docusate 100mg BID

Also known as: Colace
Docusate

Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID

Also known as: Colace, Psyllium, Polyethylene glycol, Dulcolax
Bowel medications

Eligibility Criteria

Age18 Years - 89 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Planning to be admitted to the hospital to undergo minimally-invasive urogynecologic surgery at Strong Memorial Hospital.
  • Procedures may include:
  • robot-assisted laparoscopic sacrocolpopexy
  • sacrospinous ligament suspension
  • uterosacral ligament suspension/paravaginal defect repair
  • colpocleisis
  • cystocele repair
  • Additional procedures may include:
  • hysterectomy
  • adnexectomy
  • culdoplasty
  • minimally invasive sling procedure (TVT or TOT)
  • periurethral collagen injections
  • enterocele repair

You may not qualify if:

  • Planning to undergo laparotomy.
  • Undergoing rectocele or perineocele repair as part of surgery.
  • Taking Miralax, laxatives, enemas, or suppositories daily, at the time of enrollment.
  • Presence of a colostomy.
  • Chronic kidney disease
  • Insulin-dependent diabetes mellitus
  • Known cardiac disease
  • Gastric ulcers
  • Difficulty swallowing or esophageal stricture
  • Persistent nausea and vomiting
  • Signs and symptoms consistent with bowel obstruction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Rochester

Rochester, New York, 14642, United States

Location

MeSH Terms

Interventions

Dioctyl Sulfosuccinic AcidPsylliumPolyethylene GlycolsBisacodyl

Intervention Hierarchy (Ancestors)

SuccinatesDicarboxylic AcidsAcids, AcyclicCarboxylic AcidsOrganic ChemicalsPlant ExtractsPlant PreparationsBiological ProductsComplex MixturesEthylene GlycolsGlycolsAlcoholsPolymersMacromolecular SubstancesBiomedical and Dental MaterialsManufactured MaterialsTechnology, Industry, and AgricultureCresolsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Results Point of Contact

Title
Gunhilde Buchsbaum, Division Director Urogynecology
Organization
University of Rochester

Study Officials

  • Gunhilde Buchsbaum, MD

    University of Rochester

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 5, 2010

First Posted

January 7, 2010

Study Start

November 1, 2009

Primary Completion

February 1, 2011

Study Completion

February 1, 2011

Last Updated

October 21, 2015

Results First Posted

October 21, 2015

Record last verified: 2015-09

Locations